Chemomab Therapeutics Ltd DRC (CMMB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $12.31M
Last updated: Nov 17, 2026 at 11:01 AM ET
Chemomab Therapeutics Ltd DRC (CMMB) Earnings: Report Dates and Results
Chemomab Therapeutics Ltd DRC (CMMB) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Chemomab Therapeutics Ltd DRC reported EPS of -$1.40. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CMMB has an expected report date of Mar 17, 2027.
Earnings History
Of the 25 quarters below that had an estimate, CMMB beat 17, missed 5 and matched 3. The widest gap in the table came in the quarter ended Mar 31, 2020, when EPS landed 334.78% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.40 | N/A | N/A | N/A | N/A | N/A | N/A | 1 up, 0 down | Nov 6, 2026 |
| Jun 30, 2026 | -$1.40 | N/A | N/A | N/A | N/A | N/A | N/A | 1 up, 0 down | Aug 19, 2026 |
| Mar 31, 2026 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | 1 up, 0 down | May 14, 2026 |
| Dec 31, 2025 | $0.00 | -$0.01 | N/A | +70.00% | Beat | N/A | 1 | 0 up, 0 down | Mar 19, 2026 |
| Sep 30, 2025 | $0.00 | -$0.04 | -$0.04 - -$0.04 | +90.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 13, 2025 |
| Jun 30, 2025 | -$0.02 | -$0.04 | -$0.04 - -$0.04 | +50.00% | Beat | -140.0% | 1 | 0 up, 0 down | Aug 14, 2025 |
| Mar 31, 2025 | -$0.14 | -$0.20 | N/A | +30.00% | Beat | N/A | 2 | 0 up, 0 down | May 15, 2025 |
| Dec 31, 2024 | -$0.01 | -$0.01 | -$0.01 - -$0.01 | +20.00% | Beat | N/A | 2 | 1 up, 0 down | Mar 3, 2025 |
| Sep 30, 2024 | -$0.04 | -$0.04 | -$0.04 - -$0.04 | 0.00% | In line | N/A | 2 | 1 up, 0 down | Nov 14, 2024 |
| Jun 30, 2024 | $0.05 | -$0.04 | N/A | +225.00% | Beat | N/A | N/A | N/A | Aug 21, 2024 |
| Mar 31, 2024 | -$0.06 | -$0.06 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | May 9, 2024 |
| Dec 31, 2023 | -$0.27 | -$0.02 | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Mar 7, 2024 |
| Sep 30, 2023 | -$0.07 | -$0.08 | -$0.08 - -$0.08 | +12.50% | Beat | N/A | 1 | 0 up, 0 down | Nov 9, 2023 |
| Jun 30, 2023 | -$0.14 | -$0.16 | N/A | +12.50% | Beat | N/A | N/A | 0 up, 0 down | Aug 14, 2023 |
| Mar 31, 2023 | -$0.16 | -$0.14 | -$0.16 - -$0.12 | -14.29% | Miss | N/A | 2 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$0.14 | -$0.12 | N/A | -16.67% | Miss | N/A | 1 | 0 up, 0 down | Mar 20, 2023 |
| Sep 30, 2022 | -$0.14 | -$0.92 | -$2.56 - -$0.08 | +84.78% | Beat | N/A | 2 | 0 up, 0 down | Nov 11, 2022 |
| Jun 30, 2022 | -$0.11 | -$0.72 | -$1.96 - -$0.08 | +84.72% | Beat | N/A | 2 | 0 up, 0 down | Aug 12, 2022 |
| Mar 31, 2022 | -$0.09 | -$0.68 | -$1.88 - -$0.08 | +86.76% | Beat | N/A | 2 | 0 up, 0 down | May 12, 2022 |
| Dec 31, 2021 | -$0.44 | -$0.40 | -$1.08 - -$0.08 | -10.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 9, 2022 |
| Sep 30, 2021 | -$0.05 | -$0.06 | -$0.27 - -$0.02 | +16.67% | Beat | N/A | 2 | 0 up, 0 down | Nov 12, 2021 |
| Jun 30, 2021 | -$0.05 | -$0.46 | -$0.84 - -$0.08 | +89.13% | Beat | N/A | 2 | N/A | Aug 13, 2021 |
| Mar 31, 2021 | -$0.04 | -$1.72 | N/A | +97.67% | Beat | N/A | N/A | N/A | May 13, 2021 |
| Dec 31, 2020 | -$0.06 | -$1.60 | N/A | +96.25% | Beat | -100.2% | N/A | N/A | Mar 9, 2021 |
| Sep 30, 2020 | -$0.09 | -$0.09 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 16, 2020 |
| Jun 30, 2020 | -$0.09 | -$0.11 | N/A | +18.18% | Beat | N/A | N/A | N/A | Aug 14, 2020 |
| Mar 31, 2020 | -$8.00 | -$1.84 | N/A | -334.78% | Miss | N/A | N/A | N/A | May 7, 2020 |
| Dec 31, 2019 | $31.20 | -$2.00 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 17, 2020 |
| Sep 30, 2019 | -$34.40 | -$2.93 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 15, 2019 |
| Jun 30, 2019 | -$4.00 | -$2.64 | N/A | -51.52% | Miss | N/A | N/A | N/A | Aug 5, 2019 |
| Mar 31, 2019 | -$56.00 | -$2.56 | N/A | N/A | N/A | N/A | N/A | N/A | May 22, 2019 |
| Dec 31, 2018 | -$0.12 | -$0.15 | N/A | +20.00% | Beat | N/A | N/A | N/A | Mar 12, 2019 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.17, after -$0.06 the year before. It was -$69.00 for the year ended Dec 31, 2016, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.17 | N/A |
| Dec 31, 2024 | -$0.06 | N/A |
| Dec 31, 2023 | -$0.64 | N/A |
| Dec 31, 2022 | -$0.48 | N/A |
| Dec 31, 2021 | -$0.58 | N/A |
| Dec 31, 2020 | -$8.24 | N/A |
| Dec 31, 2019 | -$63.20 | N/A |
| Dec 31, 2018 | -$0.12 | N/A |
| Dec 31, 2016 | -$69.00 | N/A |
Frequently Asked Questions About CMMB
When is Chemomab Therapeutics Ltd DRC's next earnings date?
Chemomab Therapeutics Ltd DRC's next earnings report is expected for Mar 17, 2027.
What EPS do analysts expect from CMMB next quarter?
The consensus EPS estimate for Chemomab Therapeutics Ltd DRC for the quarter ending Dec 31, 2026 is -$0.14 from 4 analysts, with estimates from -$0.27 to $0.00.
How often does CMMB beat earnings estimates?
Chemomab Therapeutics Ltd DRC beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +60.63%.
CMMB pages: Overview, Earnings, Forecast, Competitors